It is however a pretty exciting beginning, especially as afamelanotide is already approved for marketing authorisation and could be prescribed "off label" in the US tomorrow.
Scenesse implants are approved. Afemlanotide for IV/injection/topical use is not approved. Scenesse is vastly more expensive than existing proven drugs such as Alteplase (strokes). So no insurer or Medicare/Medicaid is going to pay for off-label use.
If Clinuvel was to lower the price and position Scenesse on the US market for sun protection/tanning it would be worth a fortune ( the new botox).
No it wouldn't . Afemlanotide is patent expired. A Chinese company has even patented their own alternative method of synthesis, [CUV merely has patents for delivery systems and treatments for several medical conditions.]
The FDA and all other Western drug agencies are ethically opposed to the very concept of suntans. They will never approve Scenesse, or any other tanning drug regardless of the safety profile. That is why Epitan failed. [The only possible exception would be for Mc1r deficient individuals (pale skinned redheads) on special authority by dermatologists.]
Cheap 'suntan' Scenesse would be prescribed off-label to treat EPP and other conditions killing the golden goose.
Shorts - general info, page-471
-
- There are more pages in this discussion • 278 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.00 |
Change
0.040(0.29%) |
Mkt cap ! $701.0M | |||
| Open | High | Low | Value | Volume |
| $14.10 | $14.20 | $13.97 | $452.4K | 32.15K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 126 | $14.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.12 | 66 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |